| アブストラクト | We investigated the association between the current use of individual sulphonylureas and the risk of a first-ever acute myocardial infarction (AMI) and all-cause mortality, in a population-based cohort study, using primary care data from the Clinical Practice Research Datalink database (2004-2012). New users (N = 121 869), aged >/=18 years, with at least one prescription for a non-insulin antidiabetic agent were included. The first prescription defined start of follow-up. Time-dependent Cox proportional hazard models were used to estimate the risk of a first-ever AMI and all-cause mortality associated with the use of individual sulphonylureas, and other non-insulin glucose-lowering drugs. No differences in risk of a first-ever AMI (adjusted hazard ratio [HR] 1.02, 95% confidence interval [CI] 0.70-1.50) or all-cause mortality (adjusted HR 0.97, 95% CI 0.80-1.17) were observed when comparing gliclazide use with non-gliclazide sulphonylurea use. Similar results were found for each individual sulphonylurea. As evidence is accumulating that gliclazide is no safer than other sulphonylureas, current guidelines suggesting superiority should be carefully evaluated. |
|---|
| 投稿者 | van Dalem, Judith; Brouwers, Martijn C G J; Stehouwer, Coen D A; Krings, Andre; Klungel, Olaf H; Driessen, Johanna H M; de Vries, Frank; Burden, Andrea M |
|---|
| 組織名 | Department of Clinical Pharmacy, Maastricht University Medical Centre+,;Maastricht, The Netherlands.;Care and Public Health Research Institute, Maastricht University, Maastricht, The;Netherlands.;Department of Internal Medicine, Division of Endocrinology, Cardiovascular;Research Institute Maastricht, Maastricht University Medical Centre+, Maastricht,;The Netherlands.;Department of Internal Medicine, Cardiovascular Research Institute Maastricht;(CARIM), Maastricht University Medical Centre+, Maastricht, The Netherlands.;Department of Clinical Pharmacy, Zuyderland MC, Heerlen, The Netherlands.;Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of;Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.;NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht;University, Maastricht, The Netherlands. |
|---|
